Income Tax Expense (Benefit) in USD of Karyopharm Therapeutics Inc. from 2012 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Karyopharm Therapeutics Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from 2012 to Q3 2025.
  • Karyopharm Therapeutics Inc. Income Tax Expense (Benefit) for the quarter ending September 30, 2025 was $34K, a 21.4% increase year-over-year.
  • Karyopharm Therapeutics Inc. Income Tax Expense (Benefit) for the twelve months ending September 30, 2025 was $1K, a 99.7% decline year-over-year.
  • Karyopharm Therapeutics Inc. annual Income Tax Expense (Benefit) for 2024 was $57K, a 82.4% decline from 2023.
  • Karyopharm Therapeutics Inc. annual Income Tax Expense (Benefit) for 2023 was $323K, a 12.5% decline from 2022.
  • Karyopharm Therapeutics Inc. annual Income Tax Expense (Benefit) for 2022 was $369K, a 37.7% increase from 2021.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)

Karyopharm Therapeutics Inc. Quarterly Income Tax Expense (Benefit) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $1K $34K +$6K +21.4% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-03
Q2 2025 -$5K $40K -$27K -40.3% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-11
Q1 2025 $22K $36K -$35K -49.3% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-12
Q4 2024 $57K -$109K -$239K -184% Oct 1, 2024 Dec 31, 2024 10-K 2025-02-19
Q3 2024 $296K $28K +$16K +133% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-03
Q2 2024 $280K $67K -$60K -47.2% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-11
Q1 2024 $340K $71K +$17K +31.5% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-12
Q4 2023 $323K $130K +$57K +78.1% Oct 1, 2023 Dec 31, 2023 10-K 2025-02-19
Q3 2023 $266K $12K -$33K -73.3% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-05
Q2 2023 $299K $127K +$6K +4.96% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 $293K $54K -$76K -58.5% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 $369K $73K +$194K Oct 1, 2022 Dec 31, 2022 10-K 2025-02-19
Q3 2022 $175K $45K -$61K -57.5% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 $236K $121K -$13K -9.7% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-02
Q1 2022 $249K $130K -$19K -12.8% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 $268K -$121K -$183K -295% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-29
Q3 2021 $451K $106K +$62K +141% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 $389K $134K -$3K -2.19% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 $392K $149K +$83K +126% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 $309K $62K +$60K +3000% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-17
Q3 2020 $249K $44K +$24K +120% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-03
Q2 2020 $225K $137K +$129K +1613% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 $96K $66K +$56K +560% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-04
Q4 2019 $40K $2K -$15K -88.2% Oct 1, 2019 Dec 31, 2019 10-K 2022-03-01
Q3 2019 $55K $20K +$6K +42.9% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-02
Q2 2019 $49K $8K +$25K Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-04
Q1 2019 $24K $10K -$2K -16.7% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-05
Q4 2018 $26K $17K +$8K +88.9% Oct 1, 2018 Dec 31, 2018 10-K 2021-02-24
Q3 2018 $18K $14K +$1K +7.69% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-04
Q2 2018 $17K -$17K -$35K -194% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-07
Q1 2018 $52K $12K -$11K -47.8% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09
Q4 2017 $63K $9K Oct 1, 2017 Dec 31, 2017 10-K 2020-02-26
Q3 2017 $13K Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-08
Q2 2017 $18K Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-07
Q1 2017 $23K Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-10

Karyopharm Therapeutics Inc. Annual Income Tax Expense (Benefit) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $57K -$266K -82.4% Jan 1, 2024 Dec 31, 2024 10-K 2025-02-19
2023 $323K -$46K -12.5% Jan 1, 2023 Dec 31, 2023 10-K 2025-02-19
2022 $369K +$101K +37.7% Jan 1, 2022 Dec 31, 2022 10-K 2025-02-19
2021 $268K -$41K -13.3% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-29
2020 $309K +$269K +673% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-17
2019 $40K +$14K +53.8% Jan 1, 2019 Dec 31, 2019 10-K 2022-03-01
2018 $26K -$37K -58.7% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-24
2017 $63K -$76K -54.7% Jan 1, 2017 Dec 31, 2017 10-K 2020-02-26
2016 $139K +$118M Jan 1, 2016 Dec 31, 2016 10-K 2019-02-28
2015 -$118M* -$42.3M Jan 1, 2015 Dec 31, 2015 10-K 2016-03-15
2014 -$75.8M* -$41.8M Jan 1, 2014 Dec 31, 2014 10-K 2016-03-15
2013 -$33.9M* -$18.1M Jan 1, 2013 Dec 31, 2013 10-K 2016-03-15
2012 -$15.9M Jan 1, 2012 Dec 31, 2012 10-K 2015-03-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.